Today’s Stocks: Twitter Inc (NYSE:TWTR), Cisco Systems (NASDAQ:CSCO), Kirby Corporation (NYSE:KEX), DLH Holdings Corp. (NASDAQ:DLHC), Dicerna Pharmaceuticals (NASDAQ:DRNA)

On Friday shares of Twitter Inc (NYSE:TWTR) closed at $37.10. Company’s EPS growth for next 5 years is recorded as 69.13%. Twitter Inc (NYSE:TWTR) unveils custom emoji for Taylor Swift’s Bad Blood music video.

Cisco Systems, Inc. (NASDAQ:CSCO) in last trading activity increased 1.72% to close at $29.55. Company weekly performance is 1.09% while its quarterly performance stands at 1.18%. Cisco Systems, Inc. (NASDAQ:CSCO) is -1.76% away from its 52 week high. Jefferies Group set a $29.50 price objective on Cisco Systems (NASDAQ:CSCO) in a research report released on Thursday morning. The firm currently has a hold rating on the stock.

On last trading day Kirby Corporation (NYSE:KEX) increased 0.46% to close at $81.02. Its volatility for the week is 1.63% while volatility for the month is 2.08%. KEX’s sales growth for past 5 years was 18.90% and its EPS growth for past 5 years was 16.10%. Kirby Corporation (NYSE:KEX) monthly performance is -3.21%. Kirby Corporation (NYSE:KEX) announced that Kirby present at the Bank of America Merrill Lynch 2015 Transportation Conference on Thursday, May 14, 2015.

DLH Holdings Corp. (NASDAQ:DLHC) has 5.50% insider ownership while its institutional ownership stands at 52.60%. In last trading activity company’s stock closed at $2.07.On May 7, DLH Holdings Corp. (NASDAQ:DLHC), announces financial results for its second quarter ended March 31, 2015. Revenues were $15.9 million, an increase of $1.1 million or 7.8% over prior year second quarter. The increase in revenue is due primarily to contracts awarded in 2014 and expansion of existing contracts.

On last trading day Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) fell -8.83% to close at $19.52. Its volatility for the week is 9.88% while volatility for the month is 8.92%. Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) monthly performance is 1.83%. On May 14, Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) announced it is expanding its ongoing Phase 1 study of DCR-MYC in solid tumors, multiple myeloma, or lymphoma to include a cohort of patients with pancreatic neuroendocrine tumors (PNETs) following early signs of clinical and metabolic response and tumor shrinkage in PNET patients.

Leave a Reply

Your email address will not be published. Required fields are marked *

*